Jinger Lin

Ms. Jinger Lin

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Medicine
Verified
Journal Article
Open access
JLJinger Lin
Jinger Lin
MLMin Mm Luo
Min Mm Luo
QZQianwei Mm Zhuo
Qianwei Mm Zhuo
HZHaosong Zhang
Haosong Zhang
NCNuo Chen
Nuo Chen
YHYue Han
Yue Han
Basal cell carcinoma (BCC) represents the most prevalent cancer globally. The past decade has witnessed significant advancements in BCC treatment, primarily through bibliometric studies. Aiming to perform a comprehensive bibliometric analysis of BCC treatments to comprehend the research landscape and identify trends within this domain, a dataset comprising 100 scientific publications from the Web of Science Core Collection was analyzed. Country co-operation, journal co-citation, theme bursts, keyword co-occurrence, author co-operation, literature co-citation, and field-specific references were examined using VOSviewer and CiteSpace visualization tools. These articles, published between 2013 and 2020, originated predominantly from 30 countries/regions and 159 institutions, with the USA and Germany at the forefront, involving a total of 1118 authors. The keyword analysis revealed significant emphasis on the hedgehog pathway, Mohs micrographic surgery, and photodynamic therapy. The research shows developed nations are at the forefront in advancing BCC therapies, with significant focus on drugs targeting the hedgehog pathway. This treatment avenue has emerged as a crucial area, meriting considerable attention in BCC therapeutic strategies.

7 September 2025 in Health Science Reports
Verified
Journal Article
Open access
MLMin Luo
Min Luo
JLJinger Lin
Jinger Lin
QZQianwei Zhuo
Qianwei Zhuo
LLLihang Lin
Lihang Lin
YHYue Han
Yue Han
Background and Aims: Several observational studies have reported inconsistent associations between dyslipidaemia, stains use and atopic dermatitis (AD). Nevertheless, the available data on the effects of –C‐lowering as well as TG‐lowering drugs remain inconclusive and limited. The aim of this study was to evaluate the causal association of lipid traits and long‐term use of lipid‐lowering drugs on AD risk. Methods: Drug‐targeted Mendelian randomization analyses were performed in European ancestry. Pooled statistics on low‐density lipoprotein cholesterol, triglyceride and AD were extracted from large genome‐wide association studies datasets. Instrumental variables located in and around lipid‐lowering target genes were used as proxies for therapeutic inhibition of these target genes. Inverse‐variance‐weighted approach was applied as the primary analysis. Results: We explored the role of seven lipid‐lowering target genes in AD, among which genetically proxied Niemann‐Pick C1–like 1 inhibition, a target of LDL‐C‐lowering drugs, was associated with an increased risk of AD (odds ratio, 3.03; 95% CI, 1.36–6.75; p = 0.007). This association was replicated in FinnGen cohort (odds ratio, 1.72; 95% CI, 1.09–2.72; p = 0.020). A series of sensitivity analyses confirmed the robustness of the estimates. Conclusion: We found no genetic support for the repurposing of seven lipid‐lowering drug targets for the prevention of AD. However, pharmacovigilance of AD risk in Niemann‐Pick C1–like 1 inhibitor users may be warranted.